Lirentelimab
Lirentelimab Basic information
- Product Name:
- Lirentelimab
- Synonyms:
-
- Lirentelimab
- Research Grade Lirentelimab (DHK16101)
- Research Grade Lirentelimab
- Lirentelimab (anti-Siglec-8)
- CAS:
- 2283348-97-8
- MW:
- 0
- Mol File:
- Mol File
Lirentelimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Lirentelimab Usage And Synthesis
Uses
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis[1].
in vivo
Lirentelimab (100 μg; i.v. once) significantly inhibits IgE-mediated mast cell activation in a mice model of systemic anaphylaxis[1].
| Animal Model: | Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC[1] |
| Dosage: | 100 μg |
| Administration: | Intravenous injection; 100 μg, once |
| Result: | Completely prevented passive systemic anaphylaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice. |
References
[1] Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102. DOI:10.1159/000501637
LirentelimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com